The proposed sale is small and routine for a director. Monitor the Form 4 filing to confirm whether the sale was executed; no material impact expected.
LGND drugs
LGND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $316.27entry
- T+1 · 4d ago −2.37%α −2.00% · $308.79
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Director John W. Kozarich filed a Form 144 notice of intent to sell 500 shares of Ligand Pharmaceuticals common stock, with an approximate market value of $158,659. The sale is small relative to his total holdings and the company's $6.3B market cap, representing a routine diversification move by a director.
Key Facts
- Insider: John W. Kozarich, Director
- Shares to be sold: 500 shares of common stock
- Approximate value: $158,659.25
- Broker: UBS Financial Services Inc.
- Date of notice: November 12, 2026
- Date of determination to sell: November 11, 2026
- Shares acquired via stock awards on May 25, 2018 and June 6, 2025
Financial Impact
Proposed sale of 500 shares valued at ~$158,659, representing a negligible fraction of the $6.3B market cap.
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed.
- No additional context on Kozarich's total holdings is provided in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001164 |
| Document: 0001969223-26-001164-index.html | 0001969223-26-001164 |
| Document: 0001969223-26-001164.txt | 0001969223-26-001164 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers